Vertex Pharmaceuticals Incorporated (FRA:VX1)
369.15
-0.60 (-0.16%)
At close: Oct 23, 2025
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $2.96B USD in the quarter ending June 30, 2025, with 12.06% growth. This brings the company's revenue in the last twelve months to $11.42B, up 10.46% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.42B
Revenue Growth
+10.46%
P/S Ratio
9.60
Revenue / Employee
$1.87M
Employees
6,100
Market Cap
93.35B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 139.36B |
| Deutsche Telekom AG | 120.55B |
| Allianz SE | 109.02B |
| Siemens Aktiengesellschaft | 78.30B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
| Siemens Energy AG | 38.39B |
| SAP SE | 35.89B |
| Deutsche Bank Aktiengesellschaft | 30.07B |
Vertex Pharmaceuticals News
- 18 hours ago - Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference - Business Wire
- 1 day ago - Insiders Bullish on Certain Holdings of JDOC - Nasdaq
- 1 day ago - Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Nasdaq
- 2 days ago - ClearBridge Select Strategy buys REGN, VRTX & VST; exits ICLR, PCTY & ADBE - Seeking Alpha
- 6 days ago - Vertex Pharmaceuticals (VRTX) Advances Povetacicept for Kidney Disease Treatment - GuruFocus
- 6 days ago - Vertex Pharmaceuticals (VRTX) Advances Development of Key Therapeutic - GuruFocus
- 6 days ago - Vertex IgA nephropathy asset povetacicept granted FDA rolling review - Seeking Alpha
- 6 days ago - Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week - Benzinga